Cigna Group CI
272.01
6.51
2.45%
as of 25 Sep
- Market cap
- $69.9B
- P/E
- 11.3×
Follow CI
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Cigna Group (CI) EBITDA
Cigna Group's EBITDA for fiscal 2025 was $12.0B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $12.7B. Over the past ten years it has ranged from $3.7B (fiscal 2016) to $12.2B (fiscal 2024); the current reading is higher than 91% of that period. Cigna Group ranks 3rd of 12 Healthcare Plans companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $12.0B | (1.78%) |
| FY2024 | $12.2B | 5.37% |
| FY2023 | $11.6B | 1.62% |
| FY2022 | $11.4B | 4.81% |
| FY2021 | $10.9B | (0.83%) |
| FY2020 | $11.0B | (6.59%) |
| FY2019 | $11.7B | 141.57% |
| FY2018 | $4.9B | 7.70% |
| FY2017 | $4.5B | 21.90% |
| FY2016 | $3.7B | (5.47%) |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $3.3B | 10.74% |
| Mar 2026 | $3.0B | (1.92%) |
| Dec 2025 | $3.1B | (6.35%) |
| Sep 2025 | $3.3B | 9.61% |
| 42 more quarters | Free account |
Against its own ten years
Low $3.7B
High $12.2B
Ten-year median
$11.0B
Current reading's percentile
91
EBITDA against peers
| Company | EBITDA |
|---|---|
| UNH UnitedHealth Group Incorporated compare | $26.0B |
| CVS CVS Health Corporation compare | $18.5B |
| CI Cigna Group | $12.7B |
| ELV Elevance Health, Inc. compare | $8.8B |
| HUM Humana Inc. compare | $3.5B |
| OSCR Oscar Health, Inc. compare | $632.0M |
| MOH Molina Healthcare, Inc compare | $371.0M |
| CLOV Clover Health Investments, Corp. compare | −$18.2M |
| CNC Centene Corporation compare | −$4.4B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CI
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement